KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pacific Biosciences Of California (PACB) Accounts Payables (2016 - 2026)

Pacific Biosciences Of California has reported Accounts Payables over the past 16 years, most recently at $20.8 million for Q4 2025.

  • For Q4 2025, Accounts Payables rose 25.2% year-over-year to $20.8 million; the TTM value through Dec 2025 reached $20.8 million, up 25.2%, while the annual FY2025 figure was $20.8 million, 25.2% up from the prior year.
  • Accounts Payables for Q4 2025 was $20.8 million at Pacific Biosciences Of California, up from $16.4 million in the prior quarter.
  • Over five years, Accounts Payables peaked at $21.0 million in Q1 2024 and troughed at $3.5 million in Q1 2021.
  • A 5-year average of $14.4 million and a median of $15.1 million in 2023 define the central range for Accounts Payables.
  • Biggest five-year swings in Accounts Payables: crashed 35.97% in 2021 and later surged 407.26% in 2022.
  • Year by year, Accounts Payables stood at $11.0 million in 2021, then grew by 9.33% to $12.0 million in 2022, then grew by 25.22% to $15.1 million in 2023, then increased by 10.14% to $16.6 million in 2024, then rose by 25.2% to $20.8 million in 2025.
  • Business Quant data shows Accounts Payables for PACB at $20.8 million in Q4 2025, $16.4 million in Q3 2025, and $15.1 million in Q2 2025.